Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, Mexico; Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Avenue Sierra Leona 550, Lomas 2ª. Sección, San Luis Potosí, 78210, Mexico.
Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, Mexico; Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Avenue Sierra Leona 550, Lomas 2ª. Sección, San Luis Potosí, 78210, Mexico.
Trends Biotechnol. 2018 Oct;36(10):1054-1067. doi: 10.1016/j.tibtech.2018.05.010. Epub 2018 Jul 3.
The use of innovative platforms to produce biopharmaceuticals cheaply and deliver them through noninvasive routes could expand their social benefits. Coverage should increase as a consequence of lower cost and higher patient compliance due to painless administration. For more than two decades of research, oral therapies that rely on genetically engineered plants for the production of biopharmaceuticals have been explored to treat or prevent high-impact diseases. Recent reports on the successful oral delivery of plant-made biopharmaceuticals raise new hopes for the field. Several candidates have shown protection in animal models, and efforts to establish their production on an industrial scale are ongoing. These advances and perspectives for the field are analyzed.
利用创新平台廉价生产生物制药,并通过非侵入性途径给药,可能会扩大它们的社会效益。由于成本降低和患者因无痛给药而提高了顺应性,覆盖范围将会扩大。二十多年来,人们一直在研究依赖基因工程植物生产生物制药的口服疗法,以治疗或预防高影响力疾病。最近关于成功口服递送植物源生物制药的报告为该领域带来了新的希望。一些候选药物在动物模型中显示出了保护作用,并且正在努力将其工业化生产。本文对该领域的这些进展和前景进行了分析。